

CLINICAL BIBLIOGRAPHY FOR EPSTEIN BARR VIRUS

1. Aalto SM, Linnavuori K, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998;56:186-191.
2. Abu-Shakra M, Shoenfeld Y. Parasitic infections and autoimmunity. Autoimmunity 1991;9:337-344.
3. Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 1991;181:595-608.
4. Assaad SN, Meheissen MA, Elsayed ET, et al. Study of Epstein-Barr virus serological profile in Egyptian patients with Hashimoto's thyroiditis: a case-control study. J Clin Transl Endocrinol 2020;20:1000222.
5. Balandraud N, Roudier J. Epstein-Barr virus and rheumatoid arthritis. Joint Bone Spine 2018;85:165-170.
6. Bennett JL, Mahalingam R, Wellish MC, et al. Epstein-Barr virus-associated acute autonomic neuropathy. Ann Neurol. 1996;45:345-5. doi: 10.1002/ana.410400316. PMID: 8797536
7. Birkenfeld P, Haratz N, Klein G, et al. Cross-reactivity between the EBNA-1 p107 peptide, collagen, and keratin: implications for the pathogenesis of rheumatoid arthritis. Clin Immunol Immunopathol 1990;54:14-25.
8. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022;21:296-301.
9. Blaschke S, Schwarz G, Moneke D, et al. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol 2000;27:866-873.
10. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010;67:726-738.
11. Cook SD. Does Epstein-Barr virus cause multiple sclerosis? Rev Neurol Dis. 2006;16:297-310.
12. Chang ET, Ye W, et al. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2021;30:1035-1047.
13. Dyachenko P, Smiianova O, Kurhanskaya V, et al. Epstein-Barr virus-associated encephalitis in a case-series of more than 40 patients. Waid Lek 2018;71:1224-1230.
14. Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician 2004;70:1279-1287.
15. Epstein A. Burkitt lymphoma and the discovery of Epstein-Barr virus. Br J Haematol 2012;156:777-779.
16. Fitzsimmons L, Kelly GL. EBV and apoptosis: The viral master regulator of cell fate? Viruses 2017;9:339.
17. Fujimoto H, Asaoka K, Imaizumi T, et al. Epstein-Barr virus infections of the central nervous system. Intern Med 2003;42:33-40.
18. Hacohen Y, Ciccarelli O. New evidence for Epstein-Barr virus infection as a cause of multiple sclerosis. Neurology 2022;98:605-606.

19. Harley JB, Chen X, Pujato M, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet 2018;50:699-707.
20. Harley JB, James JA. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis 2006;64:45-50.
21. Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune diseases. Front Immunol 2020;11:1-13.
22. James JA, Neas BR, Moser, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-1126.
23. Kempkes B, Robertson ER. Epstein-Barr virus latency: current and future perspectives. Curr Opin Virol 2015;14:138-144.
24. Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, et al. Use of valganciclovir in patients with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006;1:533-538.
25. Laurynenka V, Ding L, Kaufman KM, et al. A high prevalence of anti-EBNA1 heteroantibodies in systemic lupus erythematosus supports anti-EBNA1 as an origin for SLE autoantibodies. Front Immunol 2022;13:830993.
26. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008;41:298-328.
27. Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 2011;24:193-209.
28. Ohga S, Nomur A, Takeda H, et al. Immunological aspects of Epstein-Barr-Virus infection. Crit Rev Onc/Hema 2002;44:203-215.
29. Poole BD, Gross T, Maier S, et al. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun 2008;31:362-371.
30. Ridha M, Jones DG, Lerner DP, et al. The spectrum of Epstein-Barr virus infections of the central nervous system after organ transplantation. Virology 2021;18:162.
31. Schechter S, Lamps L. Epstein-Barr virus hepatitis: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 2018;142:1191-1195.
32. Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004;100:1162-1170.
33. Sutton RNP, Emond RTD, Thomas DB, et al. The occurrence of autoantibodies in infectious mononucleosis. Clin Exp Immunol 1974;17:427-436.
34. Tamoto N, Nagata K, Hara S, et al. Subclinical Epstein-Barr virus primary infection and lytic reactivation induce thyrotropin receptor autoantibodies. Viral Immunol 2019;32:362-369.
35. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-821.
36. Tiwawech D, Srivatanakul P, et al. Significance of plasma iga and igg antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2003;4:113-118.
37. Vockerodt M, Yap LF, et al. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol 2015;235:312-322.

38. Wang C, Zou SP, Chen DG, et al. Latent Epstein-Barr virus infection status and prognosis in patients with newly diagnosed Hodgkin lymphoma in Southeast China: a single-center retrospective study. Hematology 2021;26:675-683.
39. Watt T, Oberfoell S, Balise R, et al. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. J Med Virol 2012;84:1967-1974.
40. Williams MV, Cox B, Lafuse WP, et al. Epstein-Barr virus dUTPase induces neuroinflammatory mediators: implications for myalgic encephalomyelitis/chronic fatigue syndrome. Clin Ther 2019;41:848-863.
41. Wood RA, Guthridge L, Thurmond E, et al. Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmune 2021;4:100177.
42. Womack J, Jimenez M. Common questions about infectious mononucleosis. Am Fam Physician 2015;91:372-376.
43. Zhang N, Zuo Y, Jiang L, et al. Epstein-Barr virus and neurological diseases. Front Mol Biosci 2022;8:816098.